Paraneoplastic neurological syndromes (PNS) are a group of immune-mediated disorders of the nervous system that occur as remote effects of cancer, not caused by direct tumor invasion, metastasis, or treatment toxicity. These syndromes affect an estimated 1-3% of all cancer patients and can involve any part of the central or peripheral nervous system. PNS are characterized by the production of onconeural antibodies—autoantibodies directed against antigens shared between tumor cells and neurons—that mediate neuronal injury and neurodegeneration. [1]
In many cases, the neurological syndrome precedes the cancer diagnosis by months to years, making PNS an important consideration in the differential diagnosis of subacute-onset neurological disease. The identification of specific antibodies has revolutionized the field, enabling earlier diagnosis, targeted cancer screening, and classification into distinct immunopathological subtypes. Despite advances in understanding, PNS remain difficult to treat, as neuronal damage is often irreversible by the time of diagnosis. [2]
Paraneoplastic neurological syndromes represent a unique intersection of oncology and neurology, where the immune system's attempt to fight cancer inadvertently attacks the nervous system[1:1]. These conditions provide valuable insights into immune-mediated neurodegeneration and serve as models for understanding how the immune system can contribute to neurological damage in both cancer patients and those with classical neurodegenerative diseases. [3]
The fundamental mechanism involves a breakdown in immune tolerance, where tumors express neuronal antigens that trigger an immune response. This immune response, while sometimes effective at controlling tumor growth, cross-reacts with similar antigens present on neurons, leading to targeted neuronal destruction. [4]
The 2021 PNS-Care Score, published by Graus, Vogrig, Muñiz-Castrillo, and colleagues, replaced the older 2004 Euronetwork classification with a more nuanced and clinically actionable system: [5]
Clinical Phenotypes: [6]
Antibody Risk Categories: [7]
The updated criteria use a composite diagnostic score incorporating: [8]
This system improves specificity while maintaining clinical sensitivity, particularly for atypical presentations. [9]
PCD is one of the most common and devastating PNS, characterized by subacute pancerebellar dysfunction with severe truncal and appendicular ataxia, dysarthria, and nystagmus developing over weeks to months. The cerebellum is particularly vulnerable due to the high concentration of onconeural antigens in Purkinje cells. [10]
Associated antibodies and tumors: [11]
Neuropathology: Selective and severe loss of Purkinje cells throughout the cerebellar cortex, with varying degrees of Bergmann gliosis, thinning of the molecular layer, and inflammatory infiltrates. CD8+ cytotoxic T cells are the predominant effectors of neuronal destruction. [12]
Limbic encephalitis presents with subacute onset of short-term memory loss, seizures, psychiatric symptoms (anxiety, depression, psychosis), and confusion due to inflammatory involvement of the hippocampus, amygdala, and medial temporal lobes. [13]
Key antibody-tumor associations: [14]
MRI characteristically shows T2/FLAIR hyperintensity in the medial temporal lobes, which can mimic herpes simplex encephalitis. CSF typically shows lymphocytic pleocytosis and elevated protein. [15]
The most extensive paraneoplastic syndrome, encephalomyelitis involves multiple levels of the nervous system simultaneously, including cerebral cortex, limbic system, brainstem, spinal cord, dorsal root ganglia, and autonomic nervous system. Most commonly associated with anti-Hu antibodies and SCLC. [16]
Clinical features include a combination of:
Subacute sensory neuronopathy affects dorsal root ganglia, producing asymmetric, painful paresthesias and progressive proprioceptive loss leading to sensory ataxia. Most commonly associated with anti-Hu antibodies and SCLC. Pathology shows destruction of dorsal root ganglion neurons with T-cell infiltration.
LEMS is a disorder of the neuromuscular junction caused by antibodies against presynaptic P/Q-type voltage-gated calcium channels (VGCC). Approximately 50-60% of LEMS cases are paraneoplastic, predominantly associated with SCLC. Clinical features include proximal weakness (legs > arms), autonomic dysfunction (dry mouth, constipation), and hyporeflexia with post-exercise facilitation.
While most cases of stiff-person syndrome are associated with anti-GAD65 antibodies and are non-paraneoplastic, a subset with anti-amphiphysin antibodies is strongly associated with breast cancer and SCLC. Paraneoplastic stiff-person syndrome presents with progressive rigidity, painful spasms, and hyperekplexia.
OMS presents with chaotic, involuntary eye movements (opsoclonus), myoclonus, and ataxia. In children, it is strongly associated with neuroblastoma. In adults, OMS is associated with breast cancer, ovarian cancer, and SCLC. Anti-Ri (ANNA-2) antibodies are found in some adult cases.
PNS are classified into two major immunopathogenic categories based on the target antigen location:
Intracellular antigen targets (T-cell mediated):
Antibodies against intracellular antigens (Hu, Yo/CDR2, Ri, CV2, Ma2, amphiphysin) are markers of the immune response but are not directly pathogenic. Neuronal damage is primarily mediated by CD8+ cytotoxic T lymphocytes that recognize tumor-derived antigens cross-presented on neuronal MHC class I molecules. This mechanism leads to irreversible neuronal destruction, explaining the poor response to immunotherapy in these syndromes.
Evidence supporting T-cell-mediated pathogenesis:
Cell-surface antigen targets (antibody mediated):
Antibodies against neuronal surface proteins (nmda-receptor receptor, LGI1, CASPR2, AMPAR, GABA receptors) are directly pathogenic through receptor internalization, complement activation, or functional blockade. These syndromes are typically more treatment-responsive because the antibodies themselves cause neuronal dysfunction rather than permanent destruction.
A remarkable aspect of PNS is that patients often have better cancer outcomes than non-PNS patients with the same tumor type. The anti-tumor immune response that produces PNS also provides effective tumor surveillance. SCLC patients with anti-Hu antibodies, for example, tend to have limited-stage disease and longer survival, as the immune response keeps the tumor in check while unfortunately cross-reacting with the nervous system.
PNS involve activation of innate and adaptive immune pathways within the nervous system. Microglial activation, perivascular lymphocytic infiltrates, and complement deposition are common pathological features. The inflammatory microenvironment both contributes to neuronal dysfunction and represents a potential therapeutic target.
If initial cancer screening is negative, repeat screening at 3-6 month intervals for at least 2 years, as the cancer may be occult at the time of neurological presentation.
PNS must be distinguished from:
Treatment of PNS rests on three pillars:
First-line therapy:
Second-line therapy (for refractory cases):
Response patterns:
Prognosis varies markedly by syndrome and antibody type:
PNS research has provided important insights into neuroinflammation and immune-mediated neurodegeneration that are relevant to classical neurodegenerative diseases:
The study of Paraneoplastic Neurological Syndromes has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent advances in Paraneoplastic Neurological Syndromes have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:
This page was last updated: March 2026
Graus F, Vogrig A, Muñiz-Castrillo S, et al. "Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes." Neurol Neuroimmunol Neuroinflamm. Neurol Neuroimmunol Neuroinflamm. 2021. ↩︎ ↩︎
Mahdi J, Bhatt N, Engley AS. "Paraneoplastic Cerebellar Degeneration." In: StatPearls. StatPearls. 2024. ↩︎
Casali M, Grisanti S, Paoletti M, et al. "Paraneoplastic Cerebellar Degeneration Associated with Breast Cancer: A Case Report and a Narrative Review." Brain Sci. Brain Sci. 2024. ↩︎
Bien CG, Bauer J. "Paraneoplastic neurological syndromes and autoimmune encephalitis." Nervenarzt. Nervenarzt. 2014. ↩︎
Gwathmey KG, Burns TM. "Sensory neuronopathies." Muscle Nerve. Muscle Nerve. 2016. ↩︎
Bhatt T, Bhagavati S. "Neurodegeneration and the immune system: lessons from autoimmune encephalitis." J Neurol. J Neurol. 2025. ↩︎
McKeon A, Pittock SJ. "Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes." Neurotherapeutics. Neurotherapeutics. 2023. ↩︎
Martinelli I, et al. "Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management." Ann Res Oncol. Ann Res Oncol. 2024. ↩︎